4D Molecular Therapeutics (FDMT) Other financing activities (2020 - 2024)
4D Molecular Therapeutics (FDMT) posted quarterly Other financing activities of $3.1 million for Q1 2024, up 119.84% year-over-year from $1.4 million in Q2 2023, and up 510.69% quarter-over-quarter from -$758000.0 in Q2 2023.
4D Molecular Therapeutics (FDMT) Other financing activities (2020 - 2024) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Other financing activities for 5 consecutive years, with $3.1 million the latest figure, recorded in Q1 2024.
- In Q1 2024, Other financing activities rose 119.84% year-over-year to $3.1 million; the TTM figure through Mar 2024 stood at $4.6 million (up 64.58% YoY), while the FY2021 annual figure was $433000.0, changed N/A from the prior year.
- Other financing activities rose to $3.1 million in Q1 2024 per FDMT's latest filing, from -$758000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $3.1 million in Q1 2024 and bottomed at -$758000.0 in Q2 2023.
- Historically, Other financing activities has averaged $740428.6 across 5 years, with a median of $433000.0 in 2021.
- Annual changes were most pronounced in 2021 — Other financing activities surged 1880.0% — and 2023, when it soared 61.83%.
- 4D Molecular Therapeutics' Other financing activities stood at $5000.0 in 2020, then soared by 8560.0% to $433000.0 in 2021, then jumped by 102.08% to $875000.0 in 2022, then tumbled by 186.63% to -$758000.0 in 2023, then jumped by 510.69% to $3.1 million in 2024.
- Business Quant data shows FDMT's Other financing activities at $3.1 million in Q1 2024, -$758000.0 in Q2 2023, and $1.4 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 3.11 Mn |
| Mar 31, 2024 | 3.11 Mn |
| Jun 30, 2023 | -758,000.00 |
| Jun 30, 2023 | -758,000.00 |
| Mar 31, 2023 | 1.42 Mn |
| Mar 31, 2023 | 1.42 Mn |
| Mar 31, 2022 | 875,000.00 |
| Mar 31, 2022 | 875,000.00 |
| Dec 31, 2021 | 433,000.00 |
| Dec 31, 2021 | 433,000.00 |
| Mar 31, 2021 | 99,000.00 |
| Mar 31, 2021 | 99,000.00 |
| Mar 31, 2020 | 5,000.00 |
| Mar 31, 2020 | 5,000.00 |